Ruxolitinib for the treatment of inadequately controlled polycythaemia vera without splenomegaly (RESPONSE-2): a randomised, open-label, phase 3b study

Vannucchi, 2010, Insights into the pathogenesis and management of thrombosis in polycythemia vera and essential thrombocythemia, Intern Emerg Med, 5, 177, 10.1007/s11739-009-0319-3 Vardiman, 2009, The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes, Blood, 114, 937, 10.1182/blood-2009-03-209262 Levine, 2007, Role of JAK2 in the pathogenesis and therapy of myeloproliferative disorders, Nat Rev Cancer, 7, 673, 10.1038/nrc2210 Tefferi, 2013, Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study, Leukemia, 27, 1874, 10.1038/leu.2013.163 Reiter, 2016, How we identify and manage patients with inadequately controlled polycythemia vera, Curr Hematol Malig Rep, 11, 356, 10.1007/s11899-016-0311-8 Passamonti, 2004, Life expectancy and prognostic factors for survival in patients with polycythemia vera and essential thrombocythemia, Am J Med, 117, 755, 10.1016/j.amjmed.2004.06.032 Passamonti, 2008, A dynamic prognostic model to predict survival in post-polycythemia vera myelofibrosis, Blood, 111, 3383, 10.1182/blood-2007-11-121434 Marchioli, 2005, Vascular and neoplastic risk in a large cohort of patients with polycythemia vera, J Clin Oncol, 23, 2224, 10.1200/JCO.2005.07.062 Geyer, 2016, Symptomatic profiles of patients with polycythemia vera: implications of inadequately controlled disease, J Clin Oncol, 34, 151, 10.1200/JCO.2015.62.9337 Barbui, 2011, Philadelphia-negative classical myeloproliferative neoplasms: critical concepts and management recommendations from European LeukemiaNet, J Clin Oncol, 29, 761, 10.1200/JCO.2010.31.8436 Marchioli, 2013, Cardiovascular events and intensity of treatment in polycythemia vera, N Engl J Med, 368, 22, 10.1056/NEJMoa1208500 Barbui, 2015, White blood cell counts and thrombosis in polycythemia vera: a subanalysis of the CYTO-PV study, Blood, 126, 560, 10.1182/blood-2015-04-638593 Vannucchi, 2015, Ruxolitinib versus standard therapy for the treatment of polycythemia vera, N Engl J Med, 372, 426, 10.1056/NEJMoa1409002 Alvarez-Larrán, 2012, Assessment and prognostic value of the European LeukemiaNet criteria for clinicohematologic response, resistance, and intolerance to hydroxyurea in polycythemia vera, Blood, 119, 1363, 10.1182/blood-2011-10-387787 Alvarez-Larrán, 2016, Frequency and prognostic value of resistance/intolerance to hydroxycarbamide in 890 patients with polycythaemia vera, Br J Haematol, 172, 786, 10.1111/bjh.13886 Randi, 2005, Safety profile of hydroxyurea in the treatment of patients with Philadelphia-negative chronic myeloproliferative disorders, Haematologica, 90, 261 Vannucchi, 2014, Efficacy of ruxolitinib by baseline spleen volume in patients with polycythemia vera resistant to or intolerant of hydroxyurea, Blood, 124, 1840, 10.1182/blood.V124.21.1840.1840 Vannucchi, 2007, Prospective identification of high-risk polycythemia vera patients based on JAK2(V617F) allele burden, Leukemia, 21, 1952, 10.1038/sj.leu.2404854 Abdulkarim, 2011, The impact of peripheral blood values and bone marrow findings on prognosis for patients with essential thrombocythemia and polycythemia vera, Eur J Haematol, 86, 148, 10.1111/j.1600-0609.2010.01548.x Barosi, 2010, A unified definition of clinical resistance and intolerance to hydroxycarbamide in polycythaemia vera and primary myelofibrosis: results of a European LeukemiaNet (ELN) consensus process, Br J Haematol, 148, 961, 10.1111/j.1365-2141.2009.08019.x Finazzi, 2005, Acute leukemia in polycythemia vera: an analysis of 1638 patients enrolled in a prospective observational study, Blood, 105, 2664, 10.1182/blood-2004-09-3426 Crisa, 2010, A retrospective study on 226 polycythemia vera patients: impact of median hematocrit value on clinical outcomes and survival improvement with anti-thrombotic prophylaxis and non-alkylating drugs, Ann Hematol, 89, 691, 10.1007/s00277-009-0899-z Verstovsek, 2012, A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis, N Engl J Med, 366, 799, 10.1056/NEJMoa1110557 Harrison, 2012, JAK inhibition with ruxolitinib versus best available therapy for myelofibrosis, N Engl J Med, 366, 787, 10.1056/NEJMoa1110556 Verstovsek, 2016, Ruxolitinib versus best available therapy in patients with polycythemia vera: 80-week follow-up from the RESPONSE trial, Haematologica, 101, 821, 10.3324/haematol.2016.143644 Kaifie, 2016, Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms (MPN): analysis from the German SAL-MPN-registry, J Hematol Oncol, 9, 18, 10.1186/s13045-016-0242-9 Kiladjian, 2008, Pegylated interferon-alfa-2a induces complete hematologic and molecular responses with low toxicity in polycythemia vera, Blood, 112, 3065, 10.1182/blood-2008-03-143537 Quintás-Cardama, 2013, Molecular analysis of patients with polycythemia vera or essential thrombocythemia receiving pegylated interferon alpha-2a, Blood, 122, 893, 10.1182/blood-2012-07-442012 Gisslinger, 2015, Ropeginterferon alfa-2b, a novel IFNα-2b, induces high response rates with low toxicity in patients with polycythemia vera, Blood, 126, 1762, 10.1182/blood-2015-04-637280 Hasselbalch, 2015, Ruxolitinib versus standard therapy for the treatment of polycythemia vera, N Engl J Med, 372, 1670, 10.1056/NEJMc1502524 Kiladjian, 2016, Ruxolitinib treatment following interferon in patients with polycythemia vera: An analysis from the RESPONSE trial, Haematologica, 101, E1360 Ahn, 2013, Successful long-term treatment of Philadelphia chromosome-negative myeloproliferative neoplasms with combination of hydroxyurea and anagrelide, Clin Lymphoma Myeloma Leuk, 13, S300, 10.1016/j.clml.2013.05.015 Alvarez-Larrán, 2014, Busulfan in patients with polycythemia vera or essential thrombocythemia refractory or intolerant to hydroxyurea, Ann Hematol, 93, 2037, 10.1007/s00277-014-2152-7 Verstovsek, 2014, A phase 2 study of ruxolitinib, an oral JAK1 and JAK2 inhibitor, in patients with advanced polycythemia vera who are refractory or intolerant to hydroxyurea, Cancer, 120, 513, 10.1002/cncr.28441 Antonioli, 2012, Hydroxyurea-related toxicity in 3411 patients with Ph'-negative MPN, Am J Hematol, 87, 552, 10.1002/ajh.23160